STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMDW
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

Revolution Medicines (RVMD) CFO trades 20K shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported a combination of stock sales and an option exercise in company shares. On June 24, 2026, he sold 20,000 shares of common stock in multiple open-market transactions at prices generally around $167–$170 per share, executed under a Rule 10b5-1 trading plan adopted on March 24, 2026. On the same date, he exercised stock options to acquire 20,000 shares of common stock at an exercise price of $18.56 per share. After these transactions, he directly owns 123,269 shares of Revolution Medicines common stock, which includes 51,388 restricted stock units.

Positive

  • None.

Negative

  • None.
Insider Anders Jack
Role Chief Financial Officer
Sold 20,000 shs ($3.37M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 20,000 $0.00 --
Exercise Common Stock 20,000 $18.56 $371K
Sale Common Stock 4,553 $167.345 $762K
Sale Common Stock 9,496 $168.1959 $1.60M
Sale Common Stock 5,651 $169.2441 $956K
Sale Common Stock 300 $170.32 $51K
Holdings After Transaction: Stock Option (Right to Buy) — 20,600 shares (Direct, null); Common Stock — 143,269 shares (Direct, null)
Footnotes (1)
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. Includes 51,388 restricted stock units. This transaction was executed in multiple trades at prices ranging from $166.76 to $167.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $167.77 to $168.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $168.78 to $169.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $169.81 to $170.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 20,000 shares Open-market sales of common stock on June 24, 2026
Shares acquired via option exercise 20,000 shares Stock option exercise to buy common stock on June 24, 2026
Option exercise price $18.56 per share Strike price for Stock Option (Right to Buy)
Post-transaction holdings 123,269 shares Common stock directly owned after reported transactions
Restricted stock units included 51,388 RSUs Portion of reported 123,269 shares classified as RSUs
Example sale price $170.32 per share Weighted average price for a 300-share sale tranche
Sale price range $166.76–$170.60 Price ranges for multiple trade executions on June 24, 2026
Rule 10b5-1 trading plan financial
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 51,388 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Anders Jack
(Last)(First)(Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/24/2026M(1)20,000A$18.56143,269(2)D
Common Stock06/24/2026S(1)4,553D$167.345(3)138,716(2)D
Common Stock06/24/2026S(1)9,496D$168.1959(4)129,220(2)D
Common Stock06/24/2026S(1)5,651D$169.2441(5)123,569(2)D
Common Stock06/24/2026S(1)300D$170.32(6)123,269(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$18.5606/24/2026M(1)20,00003/01/202602/29/2032Common Stock20,000$020,600D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026.
2. Includes 51,388 restricted stock units.
3. This transaction was executed in multiple trades at prices ranging from $166.76 to $167.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $167.77 to $168.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $168.78 to $169.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $169.81 to $170.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ Jack Anders06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did RVMD CFO Anders Jack report on June 24, 2026?

RVMD CFO Anders Jack reported selling 20,000 shares of common stock and exercising options for 20,000 shares. All transactions occurred on June 24, 2026 and involved open-market sales and a stock option exercise in Revolution Medicines shares.

How many Revolution Medicines (RVMD) shares did the CFO sell and at what prices?

The CFO sold 20,000 RVMD common shares in several open-market trades. Reported weighted average prices for the trades were around $167–$170 per share, with detailed price ranges between $166.76 and $170.60 disclosed in the transaction footnotes.

What options did the RVMD CFO exercise in this Form 4 filing?

The CFO exercised stock options for 20,000 shares of Revolution Medicines common stock at an exercise price of $18.56 per share. These options are described as a Stock Option (Right to Buy) with a stated conversion or exercise price of $18.56.

How many RVMD shares does the CFO hold after these transactions?

After the reported transactions, the CFO directly owns 123,269 shares of Revolution Medicines common stock. This total includes 51,388 restricted stock units, as specified in the footnotes describing the components of his reported share ownership.

Were the RVMD CFO’s June 24, 2026 stock sales under a 10b5-1 plan?

Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2026. Such plans pre-schedule trades and are commonly used for routine portfolio management.

What does the Form 4 say about the RVMD CFO’s restricted stock units?

The filing notes that the CFO’s reported ownership includes 51,388 restricted stock units. Restricted stock units typically represent rights to receive shares in the future, subject to vesting conditions set by the company’s equity compensation plans.